MeSH term
Frequency | Condition_Probility | Female | 77 | 0.0 |
Humans | 631 | 0.0 |
Pregnancy | 3 | 0.0 |
Animals | 261 | 0.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 459 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 273 | 0.0 |
CDC2 Protein Kinase/*metabolism | 70 | 67.0 |
*CDC2-CDC28 Kinases | 88 | 12.0 |
Carcinoma, Hepatocellular/*enzymology/pathology | 2 | 16.0 |
Cyclin-Dependent Kinases/*metabolism | 22 | 8.0 |
Electrophoresis, Polyacrylamide Gel | 15 | 0.0 |
Enzyme Activation | 54 | 1.0 |
Hela Cells | 112 | 2.0 |
Immunoblotting | 12 | 0.0 |
Liver Neoplasms/*enzymology/pathology | 2 | 20.0 |
Proliferating Cell Nuclear Antigen/metabolism | 3 | 1.0 |
Protein-Serine-Threonine Kinases/*metabolism | 23 | 3.0 |
Adult | 20 | 0.0 |
Aged | 21 | 0.0 |
CDC2 Protein Kinase/*biosynthesis | 6 | 85.0 |
Child | 5 | 0.0 |
Cyclin B/*biosynthesis | 3 | 60.0 |
Immunohistochemistry | 25 | 0.0 |
Male | 54 | 0.0 |
Middle Aged | 18 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Prognosis | 4 | 0.0 |
Protein p53/biosynthesis | 7 | 4.0 |
Cell Cycle/physiology | 18 | 5.0 |
Cell Cycle Proteins/genetics/metabolism | 4 | 5.0 |
*Drosophila Proteins | 9 | 0.0 |
Models, Biological | 22 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 11 | 4.0 |
Recombinant Fusion Proteins/metabolism | 16 | 1.0 |
Apoptosis/*drug effects | 24 | 3.0 |
Cell Cycle/drug effects | 30 | 5.0 |
Cell Division/*drug effects | 9 | 3.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/metabolism | 2 | 5.0 |
Cyclins/metabolism | 48 | 11.0 |
Enzyme Inhibitors/*pharmacology | 17 | 2.0 |
Gene Expression | 25 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 3 | 1.0 |
Purines/*pharmacology | 5 | 29.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 7 | 4.0 |
*Apoptosis | 20 | 1.0 |
Breast Neoplasms/metabolism/pathology | 2 | 5.0 |
Cell Cycle Proteins/metabolism | 19 | 5.0 |
Cells, Cultured | 62 | 0.0 |
Cyclin B/metabolism | 36 | 36.0 |
DNA Fragmentation | 6 | 1.0 |
Drug Resistance, Neoplasm | 5 | 0.0 |
In Situ Nick-End Labeling | 7 | 1.0 |
Mitosis | 51 | 11.0 |
Paclitaxel/*pharmacology | 5 | 7.0 |
Phosphorylation | 208 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 54 | 0.0 |
Tumor Cells, Cultured | 147 | 0.0 |
Tyrosine/*metabolism | 3 | 0.0 |
cdc25 Phosphatase/metabolism | 11 | 21.0 |
Apoptosis | 17 | 0.0 |
Cell Division | 39 | 0.0 |
Genes, p53 | 5 | 1.0 |
Ploidies | 2 | 0.0 |
Magnetics | 2 | 2.0 |
Time Factors | 37 | 0.0 |
Base Sequence | 102 | 0.0 |
Flow Cytometry | 47 | 0.0 |
Heat | 2 | 0.0 |
Molecular Sequence Data | 175 | 0.0 |
Protein p53/*genetics | 4 | 2.0 |
Rats | 28 | 0.0 |
*Sequence Deletion | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 13 | 0.0 |
Adenoviridae/genetics | 5 | 1.0 |
COS Cells | 10 | 0.0 |
Cell Cycle Proteins/biosynthesis | 3 | 11.0 |
Cell Division/genetics | 6 | 1.0 |
G2 Phase/genetics | 2 | 20.0 |
Mice | 90 | 0.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Mice, Nude | 9 | 0.0 |
Mutation | 39 | 0.0 |
Proteins/*genetics | 5 | 0.0 |
*Repressor Proteins | 8 | 0.0 |
*Trans-Activators | 6 | 0.0 |
Xenograft Model Antitumor Assays | 4 | 1.0 |
Chromosome Aberrations | 2 | 0.0 |
Mitotic Spindle Apparatus/*physiology | 4 | 22.0 |
Protein Kinases/chemistry/genetics/*metabolism | 2 | 13.0 |
Cell Differentiation/genetics | 3 | 1.0 |
Gene Expression Regulation | 26 | 0.0 |
Genes, cdc/*physiology | 2 | 10.0 |
Hematopoietic Stem Cells/*cytology | 4 | 1.0 |
Amino Acid Sequence | 147 | 0.0 |
Cell Cycle | 80 | 6.0 |
Threonine/metabolism | 4 | 4.0 |
Arginine/chemistry | 2 | 3.0 |
Catalytic Domain | 3 | 1.0 |
Kinetics | 43 | 0.0 |
Protein Kinases/metabolism | 19 | 4.0 |
Substrate Specificity | 27 | 1.0 |
Antineoplastic Agents/*pharmacology | 26 | 2.0 |
Cisplatin/*pharmacology | 2 | 1.0 |
*DNA Damage | 18 | 3.0 |
*DNA Repair | 2 | 0.0 |
DNA, Complementary | 8 | 0.0 |
Down-Regulation | 18 | 0.0 |
Fibroblasts | 5 | 0.0 |
Genes, cdc | 2 | 4.0 |
Point Mutation | 7 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
CDC2 Protein Kinase/metabolism | 80 | 50.0 |
Cell Survival | 7 | 0.0 |
Cyclin D1/*metabolism | 2 | 3.0 |
Cyclin-Dependent Kinases/metabolism | 24 | 6.0 |
Cysteine Endopeptidases/metabolism | 3 | 1.0 |
G1 Phase | 16 | 5.0 |
Microscopy, Electron | 4 | 0.0 |
Multienzyme Complexes/metabolism | 3 | 1.0 |
Proteasome Endopeptidase Complex | 5 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 19 | 2.0 |
*Proto-Oncogene Proteins | 18 | 1.0 |
S Phase | 26 | 7.0 |
*G2 Phase | 17 | 47.0 |
Jurkat Cells | 12 | 0.0 |
*Mitosis | 24 | 19.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
CDC2 Protein Kinase/antagonists & inhibitors | 9 | 56.0 |
Cell Division/drug effects | 50 | 1.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 9 | 6.0 |
Cyclins/*biosynthesis | 6 | 11.0 |
DNA/analysis | 3 | 0.0 |
Head and Neck Neoplasms/*drug therapy/metabolism/pathology | 3 | 50.0 |
Protein p53/*physiology | 7 | 5.0 |
3T3 Cells | 19 | 0.0 |
Alkaloids/*pharmacology | 2 | 3.0 |
Imidazoles/*pharmacology | 3 | 4.0 |
Mitosis/*drug effects | 11 | 22.0 |
Calcium/metabolism | 2 | 0.0 |
Cell Cycle/*drug effects | 36 | 20.0 |
DNA Damage | 23 | 2.0 |
Homeostasis | 8 | 2.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 2 | 1.0 |
Meiosis/*physiology | 3 | 12.0 |
Oogenesis/physiology | 3 | 42.0 |
Protein-Tyrosine-Phosphatase/genetics/*metabolism | 2 | 4.0 |
Xenopus | 29 | 5.0 |
*Cell Cycle Proteins | 63 | 5.0 |
Cell Line | 91 | 0.0 |
*Nuclear Proteins | 27 | 1.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
Sequence Homology, Amino Acid | 46 | 0.0 |
Transfection | 61 | 0.0 |
Blotting, Western | 55 | 0.0 |
Cyclin A/metabolism | 11 | 14.0 |
Genes, Tumor Suppressor | 5 | 0.0 |
*Protein Kinases | 4 | 6.0 |
Proto-Oncogene Proteins/metabolism | 8 | 0.0 |
*Proto-Oncogene Proteins c-bcl-2 | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 20 | 0.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 2 | 1.0 |
Pyrimidines/*pharmacology | 2 | 3.0 |
Radiation-Sensitizing Agents/*pharmacology | 2 | 6.0 |
Tyrosine/metabolism | 17 | 1.0 |
Cell Cycle Proteins/physiology | 5 | 13.0 |
Dose-Response Relationship, Drug | 26 | 0.0 |
G1 Phase/*drug effects | 2 | 2.0 |
Lung Neoplasms/genetics/*pathology | 2 | 13.0 |
Microtubules/drug effects | 2 | 13.0 |
Nocodazole/pharmacology | 13 | 10.0 |
Protein Kinases/analysis | 3 | 21.0 |
cdc25 Phosphatase/physiology | 3 | 50.0 |
Apoptosis/radiation effects | 2 | 5.0 |
Cell Cycle/radiation effects | 3 | 10.0 |
Cell Division/radiation effects | 5 | 10.0 |
Cell Survival/radiation effects | 3 | 3.0 |
Dose-Response Relationship, Radiation | 9 | 2.0 |
Gamma Rays | 8 | 3.0 |
*Radiation Tolerance | 3 | 5.0 |
Caco-2 Cells | 3 | 0.0 |
Cyclins/drug effects/metabolism | 3 | 16.0 |
S Phase/*drug effects | 4 | 22.0 |
Stilbenes/*pharmacology | 3 | 5.0 |
CHO Cells | 6 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 4 | 0.0 |
Hamsters | 14 | 0.0 |
Mitosis/*physiology | 17 | 17.0 |
Serine/*metabolism | 5 | 5.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
CDC2 Protein Kinase/*antagonists & inhibitors/metabolism | 4 | 57.0 |
Cell Cycle Proteins/chemistry/*metabolism | 2 | 7.0 |
Cell-Free System | 9 | 3.0 |
Maturation-Promoting Factor/metabolism | 6 | 50.0 |
*Neoplasm Proteins | 3 | 0.0 |
Phosphotyrosine/metabolism | 4 | 0.0 |
Protein Kinases/*metabolism | 22 | 6.0 |
Protein Processing, Post-Translational | 7 | 0.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Ubiquitin/*metabolism | 2 | 1.0 |
*Xenopus Proteins | 7 | 1.0 |
G2 Phase/physiology/*radiation effects | 3 | 75.0 |
Lamins | 3 | 5.0 |
Mitosis/physiology/radiation effects | 2 | 66.0 |
Mutagenesis | 10 | 0.0 |
Nuclear Proteins/metabolism | 8 | 0.0 |
Structure-Activity Relationship | 16 | 0.0 |
Cell Line, Transformed | 7 | 0.0 |
Cyclin B/*metabolism | 14 | 46.0 |
Transformation, Genetic | 3 | 1.0 |
Amsacrine/pharmacology | 2 | 22.0 |
Apoptosis/drug effects | 16 | 2.0 |
Caspases/metabolism | 15 | 2.0 |
Comparative Study | 59 | 0.0 |
Mitosis/drug effects | 13 | 12.0 |
Mitotic Spindle Apparatus/*drug effects | 2 | 40.0 |
Protein p53/physiology | 2 | 2.0 |
Quinoxalines/*pharmacology | 3 | 33.0 |
Tumor Cells, Cultured/drug effects | 9 | 1.0 |
Antineoplastic Agents/pharmacology | 9 | 1.0 |
Enzyme Inhibitors/pharmacology | 26 | 0.0 |
Flavonoids/pharmacology | 6 | 1.0 |
Indoles/pharmacology | 3 | 1.0 |
Kidney | 4 | 1.0 |
Maleimides/pharmacology | 3 | 3.0 |
Metaphase | 4 | 2.0 |
Microtubules/*drug effects | 2 | 10.0 |
Mutagenesis, Site-Directed | 25 | 0.0 |
Nocodazole/*pharmacology | 3 | 33.0 |
Peptidylprolyl Isomerase/*metabolism | 2 | 13.0 |
Protein Kinase Inhibitors | 5 | 3.0 |
Pyridines/pharmacology | 2 | 0.0 |
Aged, 80 and over | 10 | 0.0 |
RNA Polymerase II/*metabolism | 2 | 2.0 |
14-3-3 Proteins | 9 | 6.0 |
Catalysis | 4 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
G2 Phase | 29 | 17.0 |
Protein Binding | 29 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 8 | 0.0 |
CDC2 Protein Kinase/genetics/*metabolism | 12 | 75.0 |
Cyclin B/genetics/metabolism | 5 | 41.0 |
Oocytes/physiology | 4 | 3.0 |
Peptide Mapping | 14 | 3.0 |
Xenopus laevis | 7 | 1.0 |
Cyclins/physiology | 7 | 17.0 |
Maturation-Promoting Factor/physiology | 4 | 100.0 |
Meiosis/physiology | 2 | 18.0 |
Signal Transduction | 19 | 0.0 |
Down-Regulation/drug effects | 5 | 1.0 |
Enzyme Activation/drug effects | 14 | 1.0 |
G2 Phase/*drug effects | 16 | 51.0 |
HL-60 Cells | 9 | 1.0 |
Proteins/metabolism | 6 | 0.0 |
CDC2 Protein Kinase/antagonists & inhibitors/*metabolism | 4 | 57.0 |
Molecular Weight | 12 | 0.0 |
Neurons/*enzymology/pathology | 2 | 13.0 |
Purines/pharmacology | 10 | 17.0 |
DNA, Complementary/genetics | 11 | 0.0 |
Gene Expression/drug effects | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
CDC2 Protein Kinase/*analysis | 3 | 75.0 |
Cyclins/*analysis | 5 | 12.0 |
Lymphatic Metastasis | 2 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Protein p53/analysis | 4 | 1.0 |
DNA Repair/*physiology | 2 | 1.0 |
CDC2 Protein Kinase/antagonists & inhibitors/metabolism | 4 | 50.0 |
Phosphorylation/drug effects | 15 | 1.0 |
Protein p53/genetics/*physiology | 2 | 5.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 2 | 0.0 |
CDC2 Protein Kinase/drug effects/metabolism | 5 | 71.0 |
Cell Count | 3 | 0.0 |
Cell Death/drug effects | 3 | 1.0 |
Cyclin-Dependent Kinases/drug effects/metabolism | 2 | 13.0 |
G1 Phase/drug effects | 8 | 7.0 |
G2 Phase/drug effects | 16 | 33.0 |
Cell Cycle/*drug effects/physiology | 2 | 15.0 |
Alkaloids/pharmacology | 9 | 8.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 3 | 3.0 |
DNA Primers/chemistry | 2 | 0.0 |
DNA, Antisense/pharmacology | 2 | 9.0 |
Doxorubicin/pharmacology | 7 | 3.0 |
Drug Resistance | 2 | 0.0 |
Etoposide/pharmacology | 3 | 2.0 |
G2 Phase/*physiology | 4 | 26.0 |
*Protein Kinase Inhibitors | 7 | 11.0 |
Staurosporine/analogs & derivatives | 4 | 16.0 |
Drosophila | 3 | 0.0 |
Fibroblasts/cytology/enzymology | 3 | 8.0 |
Gene Deletion | 2 | 0.0 |
Genetic Vectors | 4 | 0.0 |
Neoplasms/metabolism/*pathology | 2 | 14.0 |
Protein Kinases/*physiology | 2 | 3.0 |
Cyclin A/*metabolism | 8 | 20.0 |
Oocytes/*enzymology | 2 | 40.0 |
DNA-Binding Proteins/*genetics | 4 | 0.0 |
Autoradiography | 3 | 0.0 |
DNA/metabolism | 12 | 0.0 |
Bone Neoplasms/*pathology | 2 | 10.0 |
Osteosarcoma/*pathology | 2 | 20.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 8 | 1.0 |
Disease Models, Animal | 3 | 0.0 |
Proteins/genetics/*physiology | 2 | 1.0 |
tau Proteins/metabolism | 2 | 2.0 |
Cell Nucleus/metabolism | 14 | 0.0 |
Cyclin B/analysis | 4 | 50.0 |
Cytoplasm/metabolism | 6 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Phosphoproteins/*metabolism | 5 | 1.0 |
*Protein Biosynthesis | 5 | 1.0 |
Repressor Proteins/*metabolism | 5 | 2.0 |
CDC2 Protein Kinase/*physiology | 8 | 72.0 |
Cell Cycle Proteins/drug effects/metabolism | 4 | 28.0 |
DNA Replication/drug effects | 6 | 3.0 |
Phosphoprotein Phosphatase/genetics/*metabolism | 2 | 11.0 |
Up-Regulation/drug effects | 8 | 2.0 |
Colonic Neoplasms/*metabolism | 2 | 2.0 |
Glutathione Transferase/metabolism | 7 | 0.0 |
In Vitro | 25 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 6 | 0.0 |
Protein p53/*metabolism | 12 | 2.0 |
Transcription Factors/metabolism | 7 | 0.0 |
*Transcription Factors, TFII | 4 | 3.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Mitochondria/metabolism | 2 | 0.0 |
Proto-Oncogene Protein p21(ras)/metabolism | 5 | 6.0 |
*Reactive Oxygen Species | 2 | 7.0 |
Superoxides/metabolism | 2 | 0.0 |
Vanadates/*pharmacology | 2 | 8.0 |
Immediate-Early Proteins/genetics/*metabolism | 2 | 3.0 |
Leupeptins/pharmacology | 2 | 1.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
Subcellular Fractions/*metabolism | 2 | 10.0 |
Anticarcinogenic Agents/*pharmacology | 3 | 3.0 |
CDC2 Protein Kinase/biosynthesis | 9 | 81.0 |
Cell Survival/drug effects | 13 | 1.0 |
Genes, p53/genetics | 2 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 6 | 4.0 |
Protein p53/metabolism | 15 | 2.0 |
Proto-Oncogene Protein p21(ras)/biosynthesis | 2 | 15.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Drug Synergism | 3 | 0.0 |
G2 Phase/drug effects/*physiology | 4 | 100.0 |
Mitosis/drug effects/physiology | 2 | 16.0 |
Protein p53/metabolism/*physiology | 2 | 16.0 |
CDC2 Protein Kinase/physiology | 11 | 73.0 |
Cyclins/*physiology | 12 | 23.0 |
Virus Replication | 2 | 0.0 |
Apoptosis/drug effects/*physiology | 3 | 1.0 |
DNA-Binding Proteins/metabolism | 5 | 0.0 |
Genes, Reporter | 5 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Mice, Knockout | 7 | 0.0 |
Trans-Activation (Genetics) | 8 | 0.0 |
CDC2 Protein Kinase/*genetics | 27 | 81.0 |
Cyclin-Dependent Kinases/*genetics | 2 | 3.0 |
Protein-Serine-Threonine Kinases/*genetics | 4 | 1.0 |
Recombinant Proteins/genetics | 3 | 2.0 |
RNA, Messenger/metabolism | 20 | 0.0 |
Antibodies, Monoclonal | 7 | 0.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Liver Neoplasms | 3 | 1.0 |
Mitosis/physiology | 16 | 18.0 |
Cell Cycle Proteins/*genetics/metabolism | 2 | 3.0 |
*DNA Replication | 3 | 1.0 |
Temperature | 7 | 0.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
Genes, ras/physiology | 2 | 11.0 |
Proto-Oncogene Proteins c-raf/metabolism | 2 | 2.0 |
S Phase/drug effects | 4 | 6.0 |
Cell Line, Tumor | 15 | 0.0 |
Cell Size/drug effects | 2 | 2.0 |
Neoplasm Proteins/*metabolism | 6 | 1.0 |
Cyclin D1/metabolism | 4 | 2.0 |
Cyclin E/metabolism | 6 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 7 | 1.0 |
B-Lymphocytes/cytology/physiology | 2 | 33.0 |
Cell Cycle/*physiology | 36 | 12.0 |
Chickens | 4 | 0.0 |
Cloning, Molecular | 42 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Recombinant Proteins/metabolism | 14 | 0.0 |
Transcription Factors/genetics/*metabolism | 4 | 0.0 |
Prostatic Neoplasms/*pathology | 3 | 2.0 |
Blotting, Northern | 19 | 0.0 |
Cell Differentiation | 14 | 0.0 |
Cyclin E/biosynthesis | 2 | 25.0 |
Cyclin-Dependent Kinases/biosynthesis | 5 | 16.0 |
Cyclins/biosynthesis | 4 | 4.0 |
*G1 Phase | 5 | 10.0 |
Granulocytes/metabolism | 2 | 5.0 |
Protein-Serine-Threonine Kinases/biosynthesis | 5 | 16.0 |
Proteins/*physiology | 6 | 3.0 |
RNA/metabolism | 2 | 0.0 |
*S Phase | 5 | 7.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
DNA Primers/genetics | 9 | 0.0 |
Gene Expression Regulation, Developmental | 5 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Phenotype | 8 | 0.0 |
Tissue Distribution | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 3 | 0.0 |
Antibiotics, Antineoplastic/pharmacology | 4 | 4.0 |
*Carrier Proteins | 22 | 3.0 |
Cell Division/drug effects/physiology | 3 | 1.0 |
*Protein-Serine-Threonine Kinases | 27 | 3.0 |
Ribosomal Protein S6 Kinases/*metabolism | 2 | 8.0 |
S Phase/drug effects/physiology | 2 | 22.0 |
Signal Transduction/drug effects/*physiology | 3 | 1.0 |
Phosphotransferases/metabolism | 2 | 4.0 |
Cell Cycle/drug effects/physiology | 7 | 13.0 |
Macromolecular Substances | 12 | 0.0 |
Precipitin Tests | 22 | 0.0 |
Protein Binding/drug effects/physiology | 2 | 5.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 11 | 1.0 |
Binding Sites/genetics | 5 | 0.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 7 | 9.0 |
G2 Phase/drug effects/genetics | 4 | 80.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Retinoblastoma Protein/metabolism | 15 | 4.0 |
U937 Cells | 3 | 0.0 |
Glioma/*pathology | 3 | 5.0 |
Mitotic Index | 3 | 1.0 |
*Polyploidy | 6 | 23.0 |
Protein p53/genetics | 4 | 2.0 |
Staurosporine/pharmacology | 3 | 1.0 |
Case-Control Studies | 3 | 0.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Protein p53/drug effects/metabolism | 2 | 25.0 |
*Active Transport, Cell Nucleus | 2 | 5.0 |
Fatty Acids, Unsaturated/pharmacology | 2 | 3.0 |
Tyrosine 3-Monooxygenase/*metabolism | 2 | 2.0 |
cdc25 Phosphatase/chemistry/*metabolism | 2 | 28.0 |
Caffeine/pharmacology | 8 | 10.0 |
*Tumor Markers, Biological | 2 | 1.0 |
Active Transport, Cell Nucleus/physiology | 2 | 3.0 |
Cell Nucleus/*metabolism | 5 | 1.0 |
DNA Replication/physiology | 2 | 6.0 |
Brain Neoplasms/*genetics/pathology | 2 | 2.0 |
DNA Topoisomerases, Type I/*antagonists & inhibitors | 3 | 9.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 3 | 1.0 |
Glioma/*genetics/pathology | 2 | 6.0 |
DNA Damage/*drug effects | 3 | 6.0 |
Doxorubicin/*pharmacology | 4 | 5.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors | 3 | 6.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Genistein/*pharmacology | 6 | 18.0 |
Cyclins/*metabolism | 31 | 11.0 |
Disease Progression | 3 | 0.0 |
Immunoenzyme Techniques | 5 | 0.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Carcinoma, Hepatocellular/*pathology | 2 | 4.0 |
Cell Cycle Proteins | 2 | 11.0 |
Cyclin-Dependent Kinases/*pharmacology | 2 | 66.0 |
Cyclooxygenase Inhibitors/*pharmacology | 2 | 5.0 |
Guanine Nucleotide Exchange Factors | 3 | 3.0 |
Mitogen-Activated Protein Kinases/*pharmacology | 2 | 66.0 |
CDC2 Protein Kinase/genetics/metabolism | 8 | 53.0 |
Genotype | 2 | 0.0 |
Schizosaccharomyces/cytology/*genetics | 3 | 75.0 |
Binding Sites | 39 | 0.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/*metabolism | 2 | 4.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Histones/metabolism | 10 | 4.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 6 | 6.0 |
Response Elements/genetics | 2 | 1.0 |
Genetic Complementation Test | 16 | 2.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Protein Kinases/genetics/*metabolism | 12 | 14.0 |
Schizosaccharomyces/*enzymology/genetics/growth & development | 2 | 100.0 |
*Schizosaccharomyces pombe Proteins | 11 | 11.0 |
Cyclins/*pharmacology | 4 | 36.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Up-Regulation | 6 | 0.0 |
Liposomes | 2 | 0.0 |
Cell Differentiation/drug effects | 6 | 0.0 |
RNA, Messenger/biosynthesis/drug effects | 2 | 3.0 |
Trans-Activators/physiology | 2 | 1.0 |
Transforming Growth Factor beta/*pharmacology | 6 | 1.0 |
Cyclin B/biosynthesis | 2 | 20.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Polymerase Chain Reaction | 22 | 0.0 |
*Anaphase | 2 | 33.0 |
CDC2 Protein Kinase/chemistry/genetics/*metabolism | 3 | 100.0 |
Embryonic and Fetal Development | 2 | 0.0 |
DNA Damage/*genetics | 2 | 3.0 |
Fungal Proteins/metabolism | 4 | 2.0 |
*Genes, cdc | 4 | 18.0 |
cdc25 Phosphatase/*metabolism | 4 | 10.0 |
Cyclin-Dependent Kinases/*analysis | 4 | 21.0 |
Reference Values | 5 | 0.0 |
Caffeine/*pharmacology | 2 | 10.0 |
Cyclins/metabolism/*physiology | 2 | 20.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Amino Acid Motifs | 4 | 0.0 |
Cyclin-Dependent Kinases/genetics/*metabolism | 5 | 8.0 |
Mutation/genetics | 3 | 0.0 |
Sequence Alignment | 21 | 0.0 |
*Cell Aging | 6 | 11.0 |
Fibroblasts/cytology/drug effects/metabolism | 2 | 3.0 |
Alzheimer Disease/*enzymology/pathology | 2 | 6.0 |
Antibodies, Monoclonal/immunology | 4 | 0.0 |
Neurons/*enzymology | 2 | 2.0 |
Colchicine/metabolism | 2 | 50.0 |
Tritium | 3 | 1.0 |
Alternative Splicing | 2 | 0.0 |
Amino Acid Substitution | 5 | 0.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
DNA Replication | 16 | 4.0 |
Enzyme Induction | 2 | 0.0 |
Fungal Proteins/genetics | 4 | 2.0 |
*Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Schizosaccharomyces/genetics | 8 | 16.0 |
Sequence Deletion | 8 | 0.0 |
*Transcription, Genetic | 10 | 0.0 |
Golgi Apparatus/*metabolism | 2 | 2.0 |
*Saccharomyces cerevisiae Proteins | 4 | 0.0 |
CDC2 Protein Kinase/analysis | 4 | 57.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Fertilization | 2 | 8.0 |
Maturation-Promoting Factor/*metabolism | 3 | 75.0 |
Oocytes/cytology/drug effects/*physiology | 2 | 100.0 |
CDC2-CDC28 Kinases | 2 | 50.0 |
*Signal Transduction | 5 | 0.0 |
Ultraviolet Rays | 4 | 0.0 |
Apoptosis/*physiology | 6 | 0.0 |
Protein Biosynthesis | 4 | 0.0 |
Ranidae | 2 | 8.0 |
Signal Transduction/*physiology | 2 | 0.0 |
English Abstract | 5 | 0.0 |
Enzyme Inhibitors/metabolism | 4 | 1.0 |
Breast Neoplasms | 3 | 1.0 |
Lung Neoplasms | 2 | 1.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Mitosis/drug effects/*physiology | 2 | 18.0 |
Okadaic Acid/pharmacology | 6 | 7.0 |
Organ Specificity | 2 | 0.0 |
Cattle | 6 | 0.0 |
Endothelium, Vascular/*drug effects/metabolism | 2 | 3.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Biological Markers | 3 | 0.0 |
Cell Differentiation/*genetics | 2 | 2.0 |
DNA Primers | 20 | 0.0 |
Transcription Factors/genetics/*physiology | 2 | 1.0 |
Cytosol/metabolism | 2 | 0.0 |
G2 Phase/*radiation effects | 8 | 57.0 |
RNA, Messenger/analysis | 10 | 0.0 |
Antibiotics, Antineoplastic/*pharmacology | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
*DNA-Binding Proteins | 21 | 1.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Stomach Neoplasms | 2 | 6.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Arsenicals/*pharmacology | 2 | 7.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
Oxides/*pharmacology | 2 | 8.0 |
Biological Transport | 10 | 0.0 |
Cell Aging/*genetics | 2 | 6.0 |
Cell Cycle/drug effects/genetics | 3 | 17.0 |
Protein p53/genetics/*metabolism | 3 | 1.0 |
CDC2 Protein Kinase/genetics | 9 | 64.0 |
Fibroblasts/cytology/*physiology | 2 | 9.0 |
Gene Expression Regulation, Enzymologic | 11 | 1.0 |
Rats, Wistar | 3 | 0.0 |
Cyclin D1/genetics | 2 | 3.0 |
Cyclins/genetics | 8 | 5.0 |
Drugs, Chinese Herbal/*pharmacology | 2 | 4.0 |
Proliferating Cell Nuclear Antigen/genetics | 2 | 6.0 |
Proto-Oncogene Proteins c-myc/genetics | 2 | 3.0 |
Phosphopeptides/chemistry | 2 | 10.0 |
Threonine | 6 | 10.0 |
Cyclins/*biosynthesis/genetics | 4 | 11.0 |
Promoter Regions (Genetics) | 14 | 0.0 |
CDC2 Protein Kinase/analysis/*biosynthesis | 2 | 66.0 |
Cyclin-Dependent Kinases/analysis/*biosynthesis | 2 | 66.0 |
Protein-Serine-Threonine Kinases/analysis/*biosynthesis | 2 | 40.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Cell Division/*physiology | 4 | 2.0 |
G2 Phase/physiology | 10 | 35.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Naphthoquinones/*pharmacology | 2 | 9.0 |
*Alpha Particles | 2 | 40.0 |
Transforming Growth Factor beta/metabolism | 2 | 1.0 |
CDC2 Protein Kinase | 12 | 85.0 |
Cyclins/genetics/*metabolism | 4 | 4.0 |
*Protozoan Proteins | 2 | 5.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Fluorescent Antibody Technique | 8 | 0.0 |
Oocytes/cytology/metabolism | 3 | 17.0 |
Tetradecanoylphorbol Acetate/antagonists & inhibitors/*pharmacology | 2 | 33.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Genes, Dominant | 4 | 0.0 |
Plasmids | 10 | 0.0 |
Cyclin B/physiology | 3 | 75.0 |
Protein Conformation | 8 | 0.0 |
Testis/chemistry | 2 | 4.0 |
Conserved Sequence | 10 | 0.0 |
Genes, Fungal | 11 | 7.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
Cell Cycle/genetics | 6 | 4.0 |
Enzyme Activation/genetics | 2 | 2.0 |
Gene Expression Regulation, Neoplastic | 9 | 0.0 |
Tumor Necrosis Factor-alpha/*physiology | 2 | 0.0 |
Cell Cycle/drug effects/*physiology | 5 | 10.0 |
Dimerization | 3 | 0.0 |
Oncogene Proteins/*metabolism | 2 | 2.0 |
Cell Death | 4 | 1.0 |
Glioma/*metabolism/*pathology | 2 | 20.0 |
*Muscle Proteins | 2 | 0.0 |
Receptors, Estrogen/analysis | 2 | 0.0 |
*Cyclin-Dependent Kinases | 37 | 20.0 |
Enzyme Inhibitors/*metabolism | 2 | 2.0 |
MAP Kinase Kinase 1 | 3 | 1.0 |
MAP Kinase Kinase 2 | 2 | 4.0 |
Mimosine/pharmacology | 2 | 18.0 |
Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors | 2 | 4.0 |
Radiation, Ionizing | 6 | 4.0 |
Gene Expression Regulation, Fungal | 2 | 2.0 |
CCAAT-Enhancer-Binding Proteins | 5 | 2.0 |
Mice, Transgenic | 5 | 0.0 |
Nuclear Proteins/biosynthesis | 2 | 4.0 |
Apoptosis/*genetics | 4 | 1.0 |
Cyclin B/genetics | 2 | 50.0 |
DNA/biosynthesis | 8 | 1.0 |
G2 Phase/*genetics | 3 | 42.0 |
Nuclear Proteins/*physiology | 2 | 1.0 |
Transcription, Genetic | 22 | 0.0 |
DNA/*biosynthesis | 3 | 3.0 |
Fibroblasts/physiology | 2 | 1.0 |
Microinjections | 4 | 1.0 |
RNA, Messenger/genetics | 26 | 1.0 |
Rabbits | 3 | 0.0 |
*Tyrosine 3-Monooxygenase | 3 | 6.0 |
Apoptosis/drug effects/genetics | 2 | 5.0 |
Kidney/cytology | 2 | 1.0 |
Mitosis/*genetics | 2 | 5.0 |
Oligonucleotides, Antisense/pharmacology | 4 | 1.0 |
Protein Isoforms | 2 | 0.0 |
Caspases/physiology | 2 | 3.0 |
Peptidylprolyl Isomerase/metabolism | 2 | 25.0 |
Antibody Specificity | 4 | 0.0 |
Cell Separation | 2 | 0.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Tyrosine/chemistry | 3 | 2.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/metabolism | 3 | 5.0 |
Proto-Oncogene Proteins c-myc/metabolism | 4 | 4.0 |
Cell Cycle/*genetics | 8 | 10.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Recombinant Proteins/biosynthesis/chemistry | 2 | 2.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
DNA/*metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 9 | 0.0 |
Transcription Factors/*metabolism | 10 | 0.0 |
Nuclear Proteins/chemistry/genetics/*metabolism | 2 | 2.0 |
K562 Cells | 2 | 0.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Chromatography, Affinity | 6 | 0.0 |
Escherichia coli | 2 | 0.0 |
Models, Molecular | 5 | 0.0 |
Recombinant Proteins/biosynthesis/chemistry/metabolism | 2 | 2.0 |
*Cell Cycle | 37 | 16.0 |
Cell Cycle Proteins/*metabolism | 13 | 3.0 |
Chromatin/metabolism | 3 | 1.0 |
Nuclear Proteins/*metabolism | 8 | 1.0 |
*Promoter Regions (Genetics) | 11 | 0.0 |
*Trans-Activation (Genetics) | 5 | 0.0 |
Carbazoles/*pharmacology | 3 | 18.0 |
DNA Fragmentation/drug effects | 3 | 3.0 |
Annexin A5/metabolism | 2 | 2.0 |
Flow Cytometry/methods | 2 | 0.0 |
RNA, Messenger | 4 | 0.0 |
*Gamma Rays | 2 | 4.0 |
Radiation Tolerance | 2 | 2.0 |
Tumor Cells, Cultured/radiation effects | 2 | 5.0 |
Epidermal Growth Factor/pharmacology | 4 | 0.0 |
Liver/*cytology/*metabolism | 2 | 50.0 |
Phosphates/metabolism | 4 | 4.0 |
4-Butyrolactone/*analogs & derivatives/pharmacology | 2 | 33.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Genes, Plant | 3 | 17.0 |
*Plants, Toxic | 2 | 5.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 5 | 3.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Phosphoprotein Phosphatase/*metabolism | 4 | 4.0 |
cdc25 Phosphatase | 17 | 35.0 |
CDC2 Protein Kinase/antagonists & inhibitors/genetics/*metabolism | 2 | 66.0 |
Epitopes | 2 | 0.0 |
Genes, myc | 4 | 1.0 |
Proteins/genetics/*metabolism | 3 | 0.0 |
RNA, Antisense/pharmacology | 2 | 11.0 |
Recombinant Proteins/genetics/metabolism | 5 | 0.0 |
*Gene Expression Profiling | 4 | 0.0 |
Oligonucleotide Array Sequence Analysis | 7 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Growth Substances/*biosynthesis | 2 | 4.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
Phosphoproteins/metabolism | 7 | 1.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/metabolism | 2 | 4.0 |
Pyrimidines/*pharmacology/therapeutic use | 2 | 22.0 |
*Mitogen-Activated Protein Kinases | 2 | 0.0 |
Aphidicolin/pharmacology | 9 | 19.0 |
Genes, Lethal | 2 | 2.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Species Specificity | 8 | 0.0 |
Transcription Factors/physiology | 2 | 0.0 |
DNA Footprinting | 4 | 1.0 |
*Gene Expression Regulation | 12 | 0.0 |
Quail | 2 | 4.0 |
Cell Cycle Proteins/*genetics | 5 | 3.0 |
Insects | 2 | 1.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 7 | 0.0 |
Ubiquitin/metabolism | 3 | 1.0 |
Phosphoprotein Phosphatase/drug effects/metabolism | 2 | 66.0 |
Interferon-alpha/*pharmacology | 2 | 1.0 |
Neoplasm Staging | 6 | 0.0 |
Cell Size | 3 | 1.0 |
Drug Design | 2 | 0.0 |
*Gene Therapy | 2 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 7 | 2.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 3 | 2.0 |
Mice, Inbred Strains | 2 | 0.0 |
Ovarian Neoplasms/*genetics/pathology | 2 | 2.0 |
Protein Kinases/*genetics/metabolism | 2 | 8.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Cell Cycle Proteins/genetics | 3 | 3.0 |
DNA/genetics | 8 | 0.0 |
Serine/metabolism | 8 | 2.0 |
Adenovirus E1A Proteins/*metabolism | 2 | 6.0 |
Cercopithecus aethiops | 3 | 0.0 |
DNA-Binding Proteins/*biosynthesis | 2 | 1.0 |
Cell Cycle Proteins/genetics/*metabolism | 2 | 1.0 |
CDC2 Protein Kinase/*genetics/metabolism | 4 | 57.0 |
Cell Differentiation/*physiology | 6 | 2.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/physiology | 2 | 5.0 |
Egg Proteins/metabolism | 2 | 20.0 |
Cyclin B/*genetics | 2 | 66.0 |
Fibroblasts/cytology/metabolism/radiation effects | 2 | 25.0 |
Fibroblasts/*cytology | 2 | 6.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Cyclins/*genetics/metabolism | 3 | 6.0 |
Protein-Serine-Threonine Kinases/physiology | 2 | 2.0 |
DNA | 3 | 0.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Microscopy, Confocal | 4 | 0.0 |
Keratin/genetics | 2 | 4.0 |
Microtubule-Associated Proteins/metabolism | 3 | 2.0 |
Protein Precursors/genetics | 2 | 2.0 |
Cell Compartmentation | 7 | 2.0 |
G2 Phase/*physiology/radiation effects | 2 | 66.0 |
Microtubule-Associated Proteins/*metabolism | 4 | 3.0 |
Clone Cells | 2 | 0.0 |
Protamine Kinase/metabolism | 10 | 43.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Cyclins/*genetics | 8 | 5.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
Adenoviridae | 2 | 2.0 |
CDC2 Protein Kinase/biosynthesis/*metabolism | 2 | 100.0 |
Cyclin B/biosynthesis/*metabolism | 2 | 100.0 |
Proto-Oncogene Proteins c-myc/biosynthesis | 2 | 6.0 |
Cyclin-Dependent Kinases/*physiology | 6 | 12.0 |
Protein-Serine-Threonine Kinases/*physiology | 6 | 4.0 |
Signal Transduction/physiology | 4 | 0.0 |
Phosphoserine/analysis | 2 | 11.0 |
Antiviral Agents/*pharmacology | 2 | 1.0 |
Spodoptera | 6 | 2.0 |
Trans-Activation (Genetics)/*physiology | 2 | 1.0 |
Gene Expression Regulation, Viral | 3 | 1.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Recombinant Fusion Proteins | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Serine/chemistry | 2 | 1.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
DNA Topoisomerases, Type II/*antagonists & inhibitors | 2 | 8.0 |
Lipoproteins, LDL Cholesterol/*blood | 2 | 2.0 |
Muscular Diseases/chemically induced/epidemiology | 2 | 100.0 |
Risk Factors | 3 | 0.0 |
Cell Division/physiology | 5 | 0.0 |
Bacterial Toxins/*toxicity | 2 | 9.0 |
Threonine/chemistry | 3 | 4.0 |
CDC2 Protein Kinase/chemistry/*metabolism | 3 | 100.0 |
Phylogeny | 3 | 0.0 |
Proteins/*metabolism | 5 | 0.0 |
Sequence Analysis, DNA | 7 | 0.0 |
*cdc25 Phosphatase | 5 | 10.0 |
Histones/*genetics | 4 | 14.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Hela Cells/metabolism | 3 | 1.0 |
Phosphoproteins/genetics/*metabolism | 3 | 1.0 |
Breast Neoplasms/*metabolism | 3 | 1.0 |
CDC2 Protein Kinase/*chemistry/metabolism | 2 | 66.0 |
G1 Phase/*physiology | 2 | 4.0 |
Protein Kinase C/*physiology | 3 | 3.0 |
DNA Damage/genetics/radiation effects | 2 | 25.0 |
Hydroxyurea/pharmacology | 2 | 3.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
Cell Extracts | 5 | 3.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 3 | 0.0 |
Retinoblastoma Protein/*metabolism | 10 | 5.0 |
Transgenes | 2 | 0.0 |
Cell Fractionation | 3 | 1.0 |
Phosphothreonine/metabolism | 2 | 4.0 |
Caspases/*metabolism | 2 | 0.0 |
Silymarin/*pharmacology | 2 | 11.0 |
Paclitaxel/pharmacology | 2 | 2.0 |
Threonine/*metabolism | 5 | 12.0 |
Karyotyping | 2 | 0.0 |
Mammals | 3 | 0.0 |
Phosphopeptides/chemistry/isolation & purification | 2 | 10.0 |
Mitogens/*pharmacology | 2 | 1.0 |
Transcription Factors/*biosynthesis | 2 | 1.0 |
Interphase | 7 | 4.0 |
RNA-Binding Proteins/genetics/*metabolism | 2 | 3.0 |
G1 Phase/physiology | 6 | 8.0 |
Retinoblastoma Protein/drug effects/metabolism | 3 | 17.0 |
Thymidine/metabolism | 5 | 1.0 |
Homeodomain Proteins/metabolism | 2 | 2.0 |
*Proteins | 4 | 0.0 |
S Phase/physiology | 4 | 5.0 |
Fungal Proteins/*metabolism | 3 | 3.0 |
*ras-GRF1 | 2 | 33.0 |
CDC2 Protein Kinase/*antagonists & inhibitors | 3 | 42.0 |
Tretinoin/*pharmacology | 3 | 0.0 |
Cyclin D1 | 8 | 6.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Protein p16 | 2 | 1.0 |
Fanconi Anemia/*metabolism | 2 | 16.0 |
Carcinogens/pharmacology | 2 | 2.0 |
Alzheimer Disease/*metabolism | 2 | 0.0 |
Cross Reactions | 4 | 0.0 |
*Cyclin B | 6 | 54.0 |
Alleles | 4 | 0.0 |
*Genes, Fungal | 6 | 5.0 |
Saccharomyces cerevisiae/genetics | 4 | 0.0 |
Oncogene Proteins/metabolism | 2 | 2.0 |
Saccharomyces cerevisiae | 4 | 1.0 |
Chromatography, Gel | 4 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Cell Nucleus/enzymology | 2 | 2.0 |
Immunologic Techniques | 4 | 1.0 |
Fibroblasts/cytology | 2 | 0.0 |
Clams | 3 | 100.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
Genes, Structural | 4 | 0.0 |
Oligodeoxyribonucleotides | 12 | 1.0 |
Proliferating Cell Nuclear Antigen/biosynthesis | 2 | 4.0 |
Escherichia coli/genetics | 6 | 1.0 |
Starfish | 4 | 50.0 |
Chromatin/chemistry | 2 | 11.0 |
DNA/chemistry/metabolism | 2 | 2.0 |
Subcellular Fractions | 2 | 1.0 |
*Mitosis/drug effects | 2 | 22.0 |
CDK9 Protein Kinase | 2 | 2.0 |
Electrophoresis, Gel, Two-Dimensional | 4 | 1.0 |
Sequence Analysis | 2 | 0.0 |
Centrosome/metabolism | 2 | 10.0 |
DNA Replication/*genetics | 2 | 3.0 |
Gene Transfer Techniques | 2 | 0.0 |
Schizosaccharomyces/*genetics | 4 | 11.0 |
Blotting, Southern | 5 | 0.0 |
Carcinoma, Pancreatic Ductal/*metabolism/pathology | 2 | 18.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Pancreatic Neoplasms/*metabolism/pathology | 3 | 6.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
Cyclins/isolation & purification/*metabolism | 5 | 83.0 |
Antibodies | 3 | 0.0 |
CDC2 Protein Kinase/isolation & purification/*metabolism | 3 | 60.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 0.0 |
Recombinant Fusion Proteins/isolation & purification/metabolism | 3 | 4.0 |
Consensus Sequence | 4 | 0.0 |
Restriction Mapping | 7 | 0.0 |
Cyclins/*metabolism/physiology | 2 | 50.0 |
Gene Therapy | 2 | 0.0 |
Genes, p53/physiology | 2 | 7.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Oncogene Proteins/genetics/metabolism | 2 | 6.0 |
Serine Endopeptidases/*pharmacology | 2 | 20.0 |
Casein Kinase II | 3 | 2.0 |
Protein-Serine-Threonine Kinases/metabolism/*physiology | 2 | 9.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
DNA Damage/*physiology | 2 | 4.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Tetracycline/pharmacology | 2 | 2.0 |
Transcription Factors/*genetics/*metabolism | 2 | 1.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Keratinocytes/cytology/*drug effects/metabolism | 2 | 13.0 |
DNA Mutational Analysis | 4 | 0.0 |
*Mutation | 3 | 0.0 |
Antigens, Polyomavirus Transforming/*metabolism | 2 | 18.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Mitogen-Activated Protein Kinase 1 | 2 | 1.0 |
Oocytes/metabolism | 3 | 1.0 |
Retinoblastoma Protein/genetics/*metabolism | 2 | 4.0 |
Neoplasm Transplantation | 2 | 0.0 |
Retinoblastoma Protein/biosynthesis | 3 | 13.0 |
Proto-Oncogene Proteins c-bcl-2 | 2 | 1.0 |
Staurosporine | 5 | 5.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 2 | 2.0 |
Epithelial Cells | 3 | 0.0 |
Nuclear Proteins/*analysis/immunology/metabolism | 2 | 66.0 |
Cell Aging | 4 | 4.0 |
Hybrid Cells | 3 | 0.0 |
Cyclin-Dependent Kinases/genetics | 2 | 3.0 |
DNA, Fungal/genetics | 3 | 5.0 |
*Gene Expression | 5 | 0.0 |
Phosphoproteins/isolation & purification/*metabolism | 3 | 9.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Serine | 3 | 3.0 |
Protein Structure, Secondary | 2 | 0.0 |
*Virus Replication | 2 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Chromatin/physiology | 2 | 10.0 |
Culture Media | 2 | 0.0 |
Genes, myc/genetics | 2 | 2.0 |
*Multigene Family | 2 | 0.0 |
CDC2 Protein Kinase/*pharmacology | 2 | 100.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Embryo, Nonmammalian/cytology/physiology | 2 | 40.0 |
*Genes, Retinoblastoma | 2 | 1.0 |
Phosphotyrosine | 7 | 2.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase | 3 | 8.0 |
Cell Nucleus/physiology | 4 | 5.0 |
*Gene Amplification | 2 | 0.0 |
Schizosaccharomyces/enzymology/genetics | 2 | 28.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Cyclin B | 3 | 42.0 |
*Meiosis | 2 | 6.0 |
Progesterone/pharmacology | 2 | 1.0 |
RNA Polymerase II/metabolism | 2 | 1.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Ovum/metabolism | 2 | 18.0 |
Centrifugation, Density Gradient | 4 | 1.0 |
Myosins/*metabolism | 2 | 10.0 |
Apoptosis/*drug effects/genetics | 2 | 6.0 |
Recombinant Proteins | 2 | 0.0 |
Ethers, Cyclic/pharmacology | 3 | 8.0 |
Okadaic Acid | 3 | 6.0 |
Oligodeoxyribonucleotides/chemistry | 3 | 1.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
Carcinoma, Squamous Cell | 2 | 1.0 |
Tyrosine/analogs & derivatives/metabolism | 4 | 3.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Cell Proliferation | 2 | 1.0 |
X-Rays | 2 | 1.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 3 | 1.0 |
Mechlorethamine/*pharmacology | 2 | 100.0 |
Protein Kinases/physiology | 2 | 4.0 |
Interphase/drug effects | 2 | 7.0 |
HLA-DR Antigens/biosynthesis | 2 | 2.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Protein Transport | 3 | 0.0 |
RNA, Small Interfering/metabolism | 2 | 1.0 |
DNA Probes | 4 | 0.0 |
Multigene Family | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
*Lymphocyte Activation | 3 | 0.0 |
Proliferating Cell Nuclear Antigen | 4 | 1.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Introns | 2 | 0.0 |
Phosphoric Monoester Hydrolases/genetics/*metabolism | 2 | 4.0 |
Protein Kinases/*genetics | 6 | 5.0 |
CDC2 Protein Kinase/*biosynthesis/genetics | 2 | 100.0 |
Autoantigens/analysis | 2 | 6.0 |
Histocompatibility Antigens Class I/immunology/*physiology | 2 | 66.0 |
Oxidation-Reduction | 2 | 0.0 |
Protein Kinases/genetics/*physiology | 2 | 12.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Protein Kinases/*biosynthesis/genetics | 2 | 33.0 |
Oocytes | 2 | 1.0 |
Saccharomyces cerevisiae/metabolism | 2 | 1.0 |
Tyrosine | 4 | 3.0 |
Protein Kinases/isolation & purification/*metabolism | 3 | 15.0 |
Cell Survival/*physiology | 2 | 3.0 |
*MAP Kinase Signaling System | 2 | 1.0 |
*Threonine | 2 | 10.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
Protein Kinases/genetics | 3 | 5.0 |
Phosphopeptides/isolation & purification | 5 | 27.0 |
*Tyrosine | 2 | 4.0 |
Cyclins/analysis | 2 | 4.0 |
Adenocarcinoma/*metabolism/pathology | 2 | 1.0 |
Proto-Oncogene Proteins c-myb | 3 | 4.0 |
*Chromosomes, Human, Pair 10 | 2 | 1.0 |
Protein Kinases/genetics/isolation & purification/*metabolism | 3 | 60.0 |
*Drug Design | 2 | 2.0 |
Proto-Oncogenes | 2 | 1.0 |
*Cell Division | 5 | 3.0 |
*Oncogenes | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Schizosaccharomyces/metabolism | 2 | 11.0 |
Cell Cycle/*radiation effects | 2 | 12.0 |
Gene Expression/radiation effects | 2 | 10.0 |
RNA, Neoplasm/genetics/isolation & purification | 2 | 3.0 |
Retinoblastoma Protein/genetics/metabolism | 2 | 5.0 |
Hela Cells/enzymology | 2 | 5.0 |
Cell Death/physiology | 2 | 2.0 |
Protein Kinase C/physiology | 2 | 1.0 |
CDC2-CDC28 Kinases/metabolism | 3 | 6.0 |
DNA Repair | 2 | 0.0 |
Lymphocyte Activation | 2 | 0.0 |
Adenovirus Early Proteins | 2 | 2.0 |
Maturation-Promoting Factor/genetics/*metabolism | 2 | 100.0 |
Saccharomyces cerevisiae/enzymology/*genetics | 3 | 10.0 |
Alanine/metabolism | 2 | 5.0 |
Serine/chemistry/metabolism | 2 | 18.0 |
G1 Phase/genetics | 2 | 6.0 |
Phosphoproteins/*genetics | 2 | 0.0 |
Saccharomycetales/*genetics | 2 | 33.0 |
Oncogene Proteins, Viral/*metabolism | 2 | 5.0 |
Histones/*metabolism | 2 | 1.0 |
Repressor Proteins/genetics/metabolism | 2 | 2.0 |
Swine | 2 | 0.0 |
Thyroid Neoplasms/*metabolism/pathology | 2 | 4.0 |
CDC2-CDC28 Kinases/*metabolism | 3 | 17.0 |
Mitotic Spindle Apparatus/*metabolism | 2 | 8.0 |
cdc25 Phosphatase/analysis | 2 | 100.0 |
Dyes/pharmacology | 2 | 2.0 |
Tumor Suppressor Proteins/*metabolism | 2 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 2 | 4.0 |
Eukaryotic Cells/cytology/*metabolism | 2 | 16.0 |
Up-Regulation/physiology | 2 | 1.0 |
Ligands | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/drug effects/genetics | 2 | 25.0 |
*Viral Proteins | 3 | 1.0 |
Monensin/*pharmacology | 2 | 50.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
